Distributors Reach Settlement With Ohio Counties in Opioids Case
CLEVELAND–(BUSINESS WIRE)–AmerisourceBergen (NYSE: ABC), Cardinal Health (NYSE: CAH) and McKesson (NYSE: MCK) announced this morning that they have agreed to
Read morenews
BlackThorn Therapeutics names new Chief Executive Officer
BlackThorn Therapeutics has named William J. Martin, Ph.D., as Chief Executive Officer to Lead Next Stage of Growth. Read the
Read moreOdonate Therapeutics enrolls patients with Metastatic Breast Cancerin in a Phase 3 study of Tesetaxel
Odonate Therapeutics on Monday announces completion of enrollment in CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic
Read moreStelara data show long-term results in patients with active ulcerative colitis in phase 3 extension trial
BARCELONA, Spain–(BUSINESS WIRE)–The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new two-year data from the long-term extension of
Read moreCharles River Laboratories announces offering of $500 Million of senior notes
WILMINGTON, Mass.–(BUSINESS WIRE)–$CRL–Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it intends to offer $500 million in aggregate
Read moreRheos Medicines welcomes Barbara S. Fox as Chief Executive Officer
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Rheos Medicines, a biopharmaceutical company harnessing insights in immunometabolism to create a new class of therapeutics for patients
Read more
Genentech’s Tecentriq combo with Avastin increases overall survival in people with Unresectable Hepatocellular Carcinoma
Genentech’s Tecentriq’s First Phase III cancer immunotherapy study to show an improvement in overall survival and progression-free survival for the
Read more
Verseau launches with $50M to develop first-in-class macrophage-targeted immunotherapies and appoints George Golumbeski as Chairman of the Board
Verseau has launched with $50M to work on PSGL-1, which has been identified as lead macrophage checkpoint modulator (MCM) program
Read moreCircassia Pharmaceuticals launches Duaklir Pressair for Chronic Obstructive Pulmonary Disease (COPD)
Circassia Pharmaceuticals Inc. has launched Duaklir, aclidinium bromide and formoterol fumarate, for the maintenance treatment of patients with chronic obstructive
Read moreVertex reimburses Cystic Fibrosis Medicines Symdeko for patients ages 12 and Older, and Orkambi in children ages 2 to 5, with certain CFTR mutations in Australia
Vertex has reimburseed Cystic Fibrosis Medicines Symdeko for patients ages 12 and Older, and Orkambi in children ages 2 to
Read more